ASX-listed clinical-stage stem cell and regenerative medicine group, Cynata Therapeutics has recruited the first of two dozen adult patients suffering from respiratory failure that it is looking to enrol in a clinical trial evaluating its proprietary Cymerus mesenchymal stem cells technology.
Enrolment of the first patient will allow Cynata to kick off the clinical trial that it has dubbed “MEND”.
Originally designed to recruit COVID-19 patients admitted to intensive care with respiratory distress, Cynata’s study was expanded in late March this year to include a wider pool of patients in intensive care experiencing respiratory failure stemming from causes beyond COVID-19.
The Melbourne-based company says the trial will assess the efficacy and safety of its Cymerus mesenchymal stem cells infusions in adults suffering from respiratory failure who meet the criteria for acute respiratory distress syndrome, a type of respiratory failure associated with widespread lung inflammation.
Respiratory failure or distress including acute respiratory distress syndrome is a severe and life-threatening illness, representing a major unmet medical need, Cynata says.
Acute respiratory distress syndrome is an inflammatory process leading to build-up of fluid in the lungs due to infection, trauma and inhalation of noxious substances, with no specific pharmacological treatment options currently available.
The trial will allow us to investigate the potential benefits our mesenchymal stem cells could have in the treatment of these severely ill patients in dire need.
Our proprietary Cymerus manufacturing platform, which utilises an induced pluripotent stem cell bank sourced from a single blood donation from one donor, eliminates the reliance upon multiple donors and the need to excessively expand MSCs derived from them.
Cynata is looking to enrol 24 adult patients suffering from respiratory distress or compromised lung function to participate in the trial being conducted in NSW and Victoria.
Some of the patients are expected to have underlying acute respiratory distress syndrome, sepsis and cytokine release syndrome.
Cynata’s pre‐clinical studies suggest these conditions can potentially be treated with Cymerus mesenchymal stem cells by reducing the inflammatory reaction associated with these diseases.
Acute respiratory distress syndrome often occurs simultaneously in patients suffering from sepsis and cytokine release syndrome, according to the company.
Is your ASX-listed company doing something interesting? Contact: firstname.lastname@example.org